Clinical trials: Preserved Ejection Fraction
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Chronic Heart Failure
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection…
- Trial name
- NCT00887588
- Testing
- LCZ696, Valsartan
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 307 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8212-Preserved (NCT06979362)
- Testing
- CDR132L
- Where
- 118 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Heart Failure, Acute Decompensated Heart Failure
Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance
Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance
- Conditions
- Heart Failure, Acute Decompensated Heart Failure, Cardiorenal Syndrome, Heart Failure, Congestive
- Trial name
- NCT06174623
- Testing
- ModulHeart Support
- Where
- 5 sites in Australia, Georgia
- Volunteers
- 5 people
- Sponsor
- Puzzle Medical Devices Inc.
Non-obstructive Hypertrophic Cardiomyopathy
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2…
- Trial name
- MAVERICK-HCM (NCT03442764)
- Testing
- mavacamten
- Where
- 32 sites in United States
- Volunteers
- 59 people
- Sponsor
- MyoKardia, Inc.
Heart Failure, Heart Failure Preserved Ejection Fraction
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-2-PEF (NCT06215586)
- Testing
- Tovinontrine (CRD-750)
- Where
- 84 sites in United States, Australia and 13 more
- Volunteers
- 303 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
- Trial name
- NCT06616974
- Testing
- TX000045- Dose A, TX000045- Dose B
- Where
- 72 sites in United States, Armenia and 15 more
- Volunteers
- 191 people
- Sponsor
- Tectonic Therapeutic
Heart Failure With Preserved Ejection Fraction (HFpEF)
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
- Trial name
- NCT06560762
- Testing
- STM01
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Secretome Therapeutics